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CD40 receptor ligation evokes several crucial outcomes for the fate of an activated B cell, including proliferation and survival.
Although multiple signaling molecules in the CD40 pathways have been identiﬁed, their speciﬁc roles in regulating proliferation
and maintaining cell viability are still obscure. In this report, we demonstrate that the activation of both phosphatidylinositol
3-kinase (PI-3K) and NF-kB/Rel transcription factors is crucial for CD40-mediated proliferation. Furthermore, our data indicate
that PI-3K is indispensable for CD40-mediated NF-kB/Rel activation. This is achieved via activation of AKT and the degradation
of IkBa. Furthermore, we show that PI-3K activity is necessary for the degradation of cyclin-dependent kinase inhibitor p27
kip.
Therefore, both of these events comprise the mechanism by which PI-3K controls cell proliferation. In contrast to the absolute
requirement of PI-3K and NF-kB/Rel for proliferation, these signaling molecules are only partially responsible for CD40-mediated
survival, as blocking of PI-3K activity did not lead to apoptosis of anti-CD40-treated cells. However, the PI-3K/NF-kB pathway
is still required for CD40-induced Bcl-X gene expression. Taken together, our data indicate that multiple survival pathways are
triggered via this receptor, whereas NF-kB/Rel and PI-3K are crucial for CD40-induced proliferation. The Journal of Immu-
nology, 2000, 165: 3860–3867.
L
igation of CD40 molecule delivers crucial signals that
promote survival, proliferation, and Ig class switching of
B lymphocytes (1). CD40 ligand is expressed on activated
T cells, making this interaction essential for B-T cell cooperation.
Because of its multiple functions, the signaling pathways triggered
by CD40 are expected to be diverse. Nonetheless, a direct link
between speciﬁc signaling pathway and particular cellular out-
come remains unknown. Upon ligand binding, CD40 receptor tri-
merization facilitates clustering of the TNF receptor associated
factors 2, 3, 5, and 6 molecules. TNF receptor associated factors
serve as adapters that connect the cytoplasmic portion of CD40 to
downstream effector molecules, such as c-Jun N-terminal kinase
and NF-kB/Rel (2–4). Known signaling events occurring upon
CD40 stimulation also include activation of tyrosine kinases (Lyn),
activation of phosphatidylinositol 3-kinase (PI-3K),
3 phosphoryla-
tion of phospholipase Cg2, and activation of NF-kB/Rel transcrip-
tion factors (5). Furthermore, CD40 activation has been linked to
the up-regulation of several surface proteins (CD23, Fas, ICAM-1,
and LFA-1; Ref. 6–9) as well as anti-apoptotic molecules (Bcl-X,
A20; Ref. 10–13). It is believed that induction of these apoptosis
inhibitors causes the augmentation of cell survival induced by
CD40, although the actual mechanism accountable for their up-
regulation remains elusive. Experiments presented here are aimed
at investigating the events involved in CD40-mediated prolifera-
tion as well as survival function.
A prominent consequence of CD40 activation is induction of
NF-kB/Rel transcription factors. The NF-kB/Rel transcription fac-
tor family consists of ﬁve members that form homo and het-
erodimers that translocate to the nucleus, where they regulate tran-
scription of various target genes (14). It is believed that, by
activating these genes, NF-kB/Rel participates in both prolifera-
tion and survival in B cells. The NF-kB/Rel activity is tightly
controlled by IkB proteins that serve to sequester transcription
factor complexes in the cytoplasm (14). Data from many labora-
tories have established the sequence of biochemical events that
causes the degradation of IkB proteins and release of NF-kB/Rel
(15). Interestingly, through studies performed in the knockout (ko)
mice, it became clear that individual members of the NF-kB/Rel
family have distinct roles in the immune system. We reported pre-
viously that, although the lymphocyte development was normal in
the c-Rel ko mouse, profound functional defects were observed in
both B and T lymphocyte compartments (16, 17). Namely, c-Rel-
deﬁcient B cells were unresponsive to various mitogenic stimuli,
including CD40. Surprisingly, whereas c-Rel ko cells showed clear
defects in CD40-induced proliferation, CD40-mediated survival
was still intact (17). This observation suggested the existence of at
least two signaling pathways stemming from the CD40 receptor,
distinguishable on the basis of c-Rel involvement.
The recent generation of the PI-3K gene-targeted mouse (p85a
ko) also revealed a profoundly impaired B cell phenotype, remark-
ably similar to that of c-Rel ko mice (18, 19). It has become clear
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B lymphocytes travel via activation of PI-3K. For example, PI-
3K-deﬁcient cells were unable to mount proliferation in response
to CD40 ligation, as well as other type of mitogenic stimulation
(18). These ﬁndings underlie the importance of studying PI-3K in
the context of activation pathways in B lymphocytes. PI-3K con-
sists of a 110-kDa catalytic subunit and a tightly associated regu-
latory subunit encoded by the p85a gene that has splicing isoforms
p55a and p50a (20). Inhibition of PI-3K in IL-3-dependent cell
lines leads to apoptosis. It has been shown that PI-3K promotes
cell survival by activating AKT kinase, which phosphorylates and
inactivates pro-apoptotic molecule, Bad (21). In addition, recent
reports revealed a connection between AKT and IKKab which is
responsible for targeting IkBa for degradation and NF-kB/Rel ac-
tivation (22, 23). Based on these observations, we decided to in-
vestigate the role of PI-3K in CD40-mediated pathways that lead
to cell proliferation and/or survival and to connect these events to
the activation of NF-kB/Rel transcription factors by using c-Rel-
deﬁcient mouse.
Materials and Methods
Mice
Gene-targeted c-Rel mice were generated previously (16) and together with
normal counterparts were bred and maintained at the Weill Graduate
School of Medical Sciences of Cornell University Animal Facility under
pathogen-free conditions. Six- to 8-wk-old mice were used for experi-
ments. p85a-deﬁcient mice (PI-3K ko) were generated as described pre-
viously (18, 19) and maintained at Taconic Farms (Germantown, NY).
Reagents
PI-3K inhibitor- LY 294002 (Sigma, St. Louis, MO; Ref. 24) was dissolved
in DMSO and further diluted in cell culture medium before addition to the
cell culture at 10 mM ﬁnal concentration (ﬁnal concentration of DMSO did
not exceed 0.1%). Anti-CD40 agonistic Ab (clone 1C10, rat IgG2a) was
kindly provided by Dr. Maureen Howard (Stanford University, Stanford,
CA), afﬁnity puriﬁed from hybridoma supernatant, and used at 10mg/ml
concentration. For depleting splenic T cells, anti-Thy1.2 mAb (clone J1J)
in the form of ascites was kindly provided by Dr. Janko Nikolic-Zugic
(Sloan Kettering Institute, New York, NY), and low-tox rabbit complement
was obtained from Cedarlane Laboratory (Ontario, Canada). The following
ﬂow cytometry staining reagents were purchased from PharMingen (San
Diego, CA): PE-conjugated anti-B220, FITC-conjugated anti-CD3, and
FITC-conjugated anti-CD54 (ICAM-1). Propidium iodide for DNA frag-
mentation analysis was purchased from Sigma. Abs for immunoblotting
were obtained from the following sources: anti-p27
kip, anti-IkBa, anti-
Bcl-2, and anti-c-Rel were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA); anti-Bcl-X was purchased from Transduction Laboratories
(Lexington, KY); anti-AKT and anti-pAKT (detects phosphorylation on
S-473 residue) were obtained from New England Biolabs (Beverly, MA);
and anti-g actin was obtained from Sigma. For EMSA, anti-p50 and anti-
p65 were afﬁnity puriﬁed from rabbit serum.
Puriﬁcation of B cells and cell culture
B lymphocytes were isolated from total splenocytes by depleting T cells
with anti-Thy1.2 mAb and complement and by allowing macrophages to
adhere on the plastic surface. This protocol typically yields 95–98% pure
population of B cells that are B220
1CD3
2 as determined by ﬂow cytom-
etry. For in vitro cell culture, B cells were plated at 0.5–1 3 10
6 cells/ml
(for some experiments in triplicates) for indicated time periods in RPMI
1640 (Life Technologies, Grand Island, NY) supplemented with 10% FBS,
essential amino acids, and antibiotics. Cells were pretreated with LY
294002 inhibitor for 1 h before adding anti-CD40 Ab. At the end of culture,
cells were collected from individual wells, washed twice with PBS, and
further analyzed.
Proliferation assay
For proliferation assay, cells were plated in triplicate at 2 3 10
5 cells/well
in 96-well round-bottom plates (Fisher Scientiﬁc, Pittsburgh, PA). After
48 h of stimulation, cells were incubated with 0.5 uCi [
3H]thymidine (Am-
ersham, Arlington Heights, IL) for 5–8 h. Cells were then harvested and
thymidine incorporation into DNA was quantiﬁed by scintillation.
Flow cytometry
For two- and single-color ﬂow cytometry, cells were stained with directly
conjugated mAb on ice for 30 min and washed in PBS (1% FBS, 0.1%
NaN3). Labeled samples were analyzed on a FACScalibur instrument (Bec-
ton Dickinson, Mountain View, CA) equipped with CellQuest software.
A semiquantitative determination of the DNA content by propidium iodide
(PI) staining was used to assess the percentage of cells undergoing DNA
fragmentation (25). For PI staining, cultured cells were washed in PBS and
resuspended in a hypotonic buffer (0.1% sodium citrate, 0.1% Triton
X-100, 20 mg/ml RNaseA) containing 50 mg/ml PI at 1 3 10
6. Initially,
samples were incubated for 30 min at room temperature (to activate
RNase); thereafter, samples were kept on ice. For each sample, at least 5 3
10
3 events were collected and analyzed using a FACScalibur instrument.
The percentage of cells undergoing apoptosis is determined as the relative
number of cells with DNA content in subdiploid (subG0/1) area, char-
acteristic of apoptotic cells (25). Apoptosis data are presented as: per-
cent of speciﬁc DNA fragmentation 5 (test 2 spontaneous)/(100 2
spontaneous) 3 100.
Western blot analysis
After culture, cells were washed with PBS and lysed in RIPA buffer
(25 mM Tris (pH 7.4), 75 mM NaCl, 0.5% Triton X-100, 0.5% sodium
deoxycholate, 0.01% SDS, 2.5 mM EDTA) supplemented with the mixture
of protease and phosphatase inhibitors (100 mMN a 3VO4, 50 mM NaF, 10
mM sodium pyrophosphate, and 1 mM aprotinin, leupeptin, and PMSF).
For AKT immunoblotting, cell lysis buffer was made according to the
manufacturer’s instruction. Equal amounts of whole cell lysates, quantiﬁed
using the commercial Bio-Rad protein assay (equivalent to 10
6 cells per
sample; Richmond, CA), were loaded onto each lane of a 12.5% SDS-
PAGE gel. Polyvinylidene diﬂuoride membrane (Amersham) was used to
transfer proteins and was blocked with 2% milk in TBST buffer (10 mM
Tris-HCl (pH 8.0), 150 mM NaCl, 0.05% Tween 20) for1ha troom
temperature. Membranes were further incubated with primary Ab (condi-
tions and concentration of the Ab vary) and, after washing, incubated with
appropriate secondary HRP-conjugated secondary Ab and visualized using
commercial chemiluminescence detection kit (ECL Plus; Amersham).
EMSA
The nuclear and cytosolic fractionation procedure was performed as pre-
viously described (26). Nuclear proteins were quantiﬁed by the commercial
Bio-Rad protein assay, and EMSA was performed as described (26).
Brieﬂy, 10 mg nuclear extract proteins was incubated with 20 fmol of
32P-labeled kB probe dissolved in an appropriate buffer. The DNA-protein
complexes were resolved on a native 6% polyacrylamide gel, dried, and
exposed on a ﬁlm for autoradiography. For Ab-inhibition experiments, op-
timal amount of Ab was determined by using puriﬁed proteins. Appropriate
FIGURE 1. PI-3K activity is necessary for CD40-mediated prolifera-
tion. Puriﬁed splenic B lymphocytes from wt and c-Rel ko mice were
cultured for 48 h in triplicates at 2 3 10
5 cells/well with indicated stimuli.
LY 294002 was used at 20 mM to pretreat cells for 1 h. Anti-CD40 Ab was
added at 10 mg/ml. [
3H]Thymidine incorporation was measured on the
b-scintillation counter. ccpm, Corrected cpm.
3861 The Journal of ImmunologyAb was incubated with a mixture of nuclear extract and poly(dI-dC) in 13
DNA binding buffer on ice for 30 min before the addition of
32P-labeled kB
probe. The reaction was continued for another 15 min before it was loaded
on a native 6% polyacrylamide gel.
Results
PI-3K inhibitor blocks CD40-induced proliferation
Cross-linking of CD40 on the cell surface by agonistic Ab or li-
gand binding generates a very strong proliferation signal for nor-
mal B cells. In dissecting the signaling pathway emanating from
CD40, we observed that NF-kB/Rel plays a crucial role in CD40-
mediated proliferation. Speciﬁcally, c-Rel-deﬁcient cells exhibit
very low levels of proliferation when stimulated with agonistic
anti-CD40 Ab (Ref. 17 and Fig. 1). While searching for upstream
signaling molecules that are responsible for CD40-mediated NF-
kB/Rel activation, we learned that PI-3K-deﬁcient B lymphocytes
were also hyporesponsive to anti-CD40-induced proliferation (18,
27). These observations thus prompted us to further investigate the
relationship between PI-3K and NF-kB/Rel. We took advantage of
the well-characterized PI-3K inhibitor LY 294002 that speciﬁcally
blocks the ATP-binding sites of the p110 catalytic subunit (24).
FIGURE 2. PI-3K is essential for NF-kB/Rel
nuclear translocation. A, Nuclear extracts were iso-
lated from wt and c-Rel ko B cells (10 3 10
6 cells/
stimuli) stimulated as indicated for 4 h. Cells were
pretreated with LY 294002 for 1 h before addition
of anti-CD40 or anti-IgM Abs. EMSA was per-
formed by using
32P-labeled Ig gene kB site as a
probe. B, Nuclear extracts from wt and c-Rel ko B
cells treated for 4 h with 10 mg/ml anti-CD40 Ab
were incubated with indicated Abs (1 mg/sample
anti-p50 and anti-p65, 0.02 mg/sample anti-c-Rel).
Lane without Abs contains 5 mg/sample control
polyclonal rabbit Ig. EMSA was performed as
above. Ab-induced effect is evident in wt lanes
treated with Abs where bands are either super-
shifted or diminished, which indicates that these
complexes contain p65, p50, and c-Rel proteins. In
the lanes containing c-Rel ko samples, only anti-
p50 and anti-p65 induce diminishment of com-
plexes, whereas anti-c-Rel does not have any effect
because these cells are c-Rel-deﬁcient. C, Cyto-
plasmic extracts from B cells used in B were sub-
jected to immunoblot analysis with anti-p50 Ab.
3862 ROLE OF PI-3K AND NF-kB/Rel IN CD40 SIGNALINGWe found that LY 294002 completely abrogates proliferation in-
duced via CD40 in both wild-type (wt) and c-Rel ko B cells (Fig.
1). This is not due to the increased rate of cell death, because CD40
stimulation maintains cell viability following the treatment with
the PI-3K inhibitor, as shown below in Fig. 5.
PI-3K activity is necessary for NF-kB/Rel nuclear translocation
induced via CD40
A critical consequence of CD40 signaling in B lymphocytes in-
volves high and sustained activation of the NF-kB/Rel transcrip-
tion factors (Ref. 28; S.A. and H.-C.L., unpublished observations).
Because PI-3K inhibition resulted in a serious impairment in pro-
liferation that was similar to that of c-Rel-deﬁcient B cells, we
investigated whether PI-3K is connected to NF-kB/Rel activation
in splenic B lymphocytes. Intriguingly, using the EMSA, we ob-
served that PI-3K blocking completely prevents nuclear transloca-
tion and activation of NF-kB/Rel complexes upon CD40 and anti-
IgM stimulation (Fig. 2A). The inhibition was observed in both wt
and c-Rel ko B cells. Note that c-Rel-deﬁcient cells mobilize NF-
kB/Rel complexes to a lesser degree than the wt cells, due to the
lack of the predominant c-Rel member. Translocated complexes in
c-Rel ko B cells consist of p65 and p50 proteins as identiﬁed by an
Ab inhibition assay shown in Fig. 2B. Furthermore, we found that
the inhibition of NF-kB/Rel activity by the PI-3K antagonist is not
due to diminishment of NF-kB/Rel proteins, because their expres-
sion level in the cytoplasm (in both wt and c-Rel ko cells) re-
mained unchanged regardless of the treatment (Figs. 2C,3 B, and
data not shown). Rather, these results demonstrate that PI-3K spe-
ciﬁcally affects nuclear translocation of NF-kB/Rel complexes.
B cells isolated from the PI-3K ko mouse show impaired
NF-kB/Rel activation
In an effort to exclude possible nonspeciﬁc effects of the chemical
compound serving as pharmacological PI-3K inhibitor, we used
PI-3K-deﬁcient mice (p85a ko) (18) to assay for NF-kB/Rel ac-
tivation. We found that p85a ko B cells stimulated via CD40 li-
gation completely lack the induction of nuclear NF-kB/Rel com-
plexes (Fig. 3A), in a manner similar to that observed with the use
of PI-3K inhibitor (Fig. 2A). Therefore, these data strongly support
our conclusion that PI-3K action is required for NF-kB/Rel acti-
vation. Despite the marked absence of the nuclear NF-kB/Rel pro-
teins, cytoplasmic c-Rel is normally present in p85a ko B cells
(Fig. 3B), suggesting that PI-3K is crucial for permitting nuclear
translocation of the NF-kB/Rel complexes. Previous studies have
demonstrated that IkBa degradation is required for NF-kB/Rel
activation and nuclear translocation (14, 15). Considering recently
published data (22, 23), it was reasonable to suggest that the di-
minishment of nuclear NF-kB/Rel caused by PI-3K inhibition is
caused by a block in IkBa degradation. To test this hypothesis, we
performed Western blot analysis of the IkBa inhibitor expression
in normal and p85a-deﬁcient mice. As shown in Fig. 3C, degra-
dation of IkBa occurred upon CD40 treatment in wt mice (lane 2),
but was prevented in the B cells that lack PI-3K activity (lane 4).
This result conﬁrms that PI-3K activation represents the main
pathway that conveys activation signals from the CD40 receptor to
the complex machinery that directs IkBa degradation via proteo-
some pathways.
PI-3K activity controls down-regulation of the cell cycle
inhibitor p27
kip
A recent report on the Kit225 cell line stimulated with IL-2 con-
cluded that PI-3K promotes proliferation via down-regulating cell
cycle inhibitor p27
kip (29). p27
kip is a cyclin-dependent kinase
(CDK) inhibitor whose expression level is reduced by an ubiq-
uitin-proteosome-dependent mechanism during G1 phase of the
cell cycle (30). Degradation of p27
kip CDK inhibitor is necessary
for the activation of CDK kinases and subsequent cell cycle pro-
gression (30). By examining p27
kip expression levels in B lym-
phocytes, we discovered that PI-3K inhibitor prevents CD40-in-
duced down-regulation of p27
kip over a 24- to 48-h period (Fig.
4A). Consistent with the results obtained using the PI-3K inhibitor
LY294002, we conﬁrm that p27
kip down-regulation is also pre-
vented in mice deﬁcient for PI-3K activity (Fig. 4B). Taken to-
gether, our data show that PI-3K regulates both NF-kB/Rel acti-
vation and p27
kip CDK inhibitor degradation, events that are
essential for cellular proliferation.
FIGURE 3. p85a-deﬁcient mouse shows diminished NF-kB/Rel activ-
ity. A, Nuclear extracts were isolated from wt and p85a ko B cells stim-
ulated for4ha sindicated. EMSA was performed by using
32P-labeled Ig
gene kB site as a probe. B, Cytoplasmic extracts from cells used in A were
immunoblotted with anti-c-Rel Ab. All lanes contained equal amount of
protein as determined by spectrometry. C, Cytoplasmic extracts from wt
and p85a ko B cells that were stimulated for 2 h with 10 mg anti-CD40 Ab
were subjected to immunoblot analysis with anti-IkBa Ab and subse-
quently reprobed for the expression of g-actin, which served as a loading
control.
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inhibition
Apart from causing cellular activation, CD40 is also crucial for
maintaining the viability of B lymphocytes both in vitro and in
vivo (1, 2). Our studies led us to further test whether PI-3K and
NF-kB/Rel contribute to the CD40-mediated survival pathway. In
accordance with our previous ﬁnding (17), CD40 treatment pro-
vides the same level of protection from spontaneous apoptosis to
both wt and c-Rel ko B cells (Fig. 5). LY 294002, when applied
alone, induces cell death in both wt and c-Rel ko B lymphocytes
(Fig. 5), suggesting that PI-3K is important for maintaining the
viability of resting splenic B cells. Intriguingly, CD40 stimulation
can partially rescue cell death induced via LY 294002, in both wt
and c-Rel-deﬁcient B cells (Fig. 5). We conﬁrmed these ﬁndings
by counting the actual number of live cells, where we observed
that in all experiments the number of live cells was comparable in
nontreated control samples and samples treated with combination
of LY294002 and CD40 stimulation (data not shown). These data
suggest that certain aspects of CD40-stimulated apoptosis protec-
tion are operational, even in the absence of both c-Rel and PI-3K
activity. To ﬁnd effectors of the CD40-mediated survival, we
tested known apoptosis-blocking molecules for their role in this
pathway.
PI-3K inhibitor blocks phosphorylation of AKT induced by
CD40 stimulation
Previous studies in several cell systems, including B lymphocytes,
demonstrated that AKT kinase is one of the primary targets of
PI-3K (31). Because AKT was shown to prevent apoptosis (21,
32), we investigated its role in CD40-mediated survival pathway.
As shown in Fig. 6, AKT phosphorylation occurs within 15 min
after anti-CD40 treatment, and increases up to 1 h poststimulation.
However, pretreatment of cells with LY294002 compound po-
tently blocks phosphorylation, while having no effect on overall
levels of nonphosphorylated AKT in the cytoplasm (Fig. 6). This
result veriﬁes that, in B lymphocytes, CD40 activates AKT exclu-
sively via PI-3K pathway. Nonetheless, the PI-3K/AKT survival
pathway contributes only partially to the CD40-mediated apoptosis
protection in splenic B lymphocytes, because we observed that
lack of PI-3K activation did not signiﬁcantly alter CD40-mediated
survival function (Fig. 5).
Bcl-X expression is impaired by lack of c-Rel and by PI-3K
inhibition
Bcl-X is recognized to be a major anti-apoptotic protein that is
induced upon CD40 stimulation (10, 12, 13). To test whether this
protein confers CD40-mediated protection from LY 294002-in-
ﬂicted cell death, we analyzed its expression in wt and c-Rel ko B
cells that were stimulated with CD40 in the presence/absence of
the PI-3K inhibitor (Fig. 7A). Surprisingly, we observed a com-
plete absence of Bcl-X expression in c-Rel deﬁcient cells. We
further performed experiments to assess Bcl-X expression in p85a
ko B cells. As shown in Fig. 7B, p85a-deﬁcient B cells also lack
Bcl-X induction upon CD40 stimulation. This and our other ob-
servations (A.O. and H.-C.L., unpublished data) thus indicate that
Bcl-X is directly regulated via c-Rel. Bcl-X induction in wt cells
was also signiﬁcantly perturbed by addition of the PI-3K inhibitor
FIGURE 4. CD40-induced PI-3K activation
controls down-regulation of p27. A, Splenic B
cells isolated from normal (wt) mouse were cul-
tured at 1 3 10
6 cells/ml with indicated stimuli.
LY 294002 was used at 20 mM to pretreat cells
for 1 h. Anti-CD40 Ab was added at 10 mg/ml.
Lysates of cells collected at 24-h, 36-h, and 48-h
time points were subjected ﬁrst to immunoblot-
ting with anti-p27
kip Ab. Blots were further re-
probed with anti-actin Ab to serve as loading
control. B, Splenic B cells isolated from normal
(wt) and p85a ko mice were cultured at 2 3 10
6
cells/mlwithindicatedstimuli.Anti-CD40oranti-
IgM Abs were added at 10 mg/ml. Lysates of
cells collected at 24 h were subjected to immu-
noblotting with anti-p27
kip Ab.
FIGURE 5. CD40 signaling blocks apoptosis induced by PI-3K inhib-
itor. Isolated splenic B cells (2 3 10
6 cells/ml) from wt and c-Rel ko mouse
were cultured for 24 h in the presence of indicated stimuli. LY294002 was
used at 20 mM to pretreat the cells, and 10 mg/ml anti-CD40 was added.
Upon culture, cells were labeled with PI and analyzed by ﬂow cytometry.
Data shown represent mean values from three representative experiments.
3864 ROLE OF PI-3K AND NF-kB/Rel IN CD40 SIGNALINGand correlates with the compound’s ability to inhibit NF-kB/Rel
activity (Fig. 2A). In contrast to Bcl-X, Bcl-2 is constitutively
present in B lymphocytes and remained constant and unaffected by
c-Rel deﬁciency or PI-3K inhibition in all samples tested (Fig. 7A).
Taken together, these data indicate that Bcl-X expression is regu-
lated by both NF-kB/Rel and PI-3K, representing one of the mul-
tiple survival pathways triggered via CD40.
Discussion
It has been unclear as to whether or not CD40-mediated prolifer-
ative and survival effects are separable events that are controlled
by distinct signaling pathways. Our study argues for the existence
of at least two parallel signaling pathways stemming from the
CD40 receptor that are distinguishable based on their reliance on
the NF-kB/Rel transcription factor. In splenic B cells, we found
that PI-3K and NF-kB/Rel pathway is necessary for CD40-induced
proliferation. In contrast, this pathway is not the only survival
pathways used by CD40, because cells remain viable even though
this pathway is blocked. These data thus suggest the existence of
other survival pathways that are independent of NF-kB/Rel and
Bcl-X.
One of the intriguing ﬁndings of this study is a deﬁnitive link
between PI-3K, NF-kB/Rel activation, and cell proliferation (Fig.
8). Using PI-3K ko mice or pharmacological inhibitor LY294002,
we showed that PI-3K controls the nuclear translocation of CD40-
induced NF-kB/Rel complexes, through regulation of IkBa deg-
radation. Together with two recent reports showing a direct inter-
action between AKT and IKKa in cell lines (22, 23), we propose that
PI-3K may regulate IkBa degradation in splenic B lymphocytes via
AKT. Indeed, we showed that AKT phosphorylation and activation is
blocked when PI-3K activity is inhibited. Thus, our study established
the necessary signaling pathway responsible for CD40-mediated pro-
liferation that involves PI-3K and NF-kB/Rel activation.
In dissecting the mechanism by which CD40 controls cell pro-
liferation, we also found that PI-3K-mediated cell cycle progres-
sion involves p27
kip down-regulation. There is no experimental
evidence to connect p27
kip down-regulation and NF-kB/Rel acti-
vation. However, it is most likely that these two PI-3K-mediated
events are independently regulated. First, it is noticeable that these
two events occur at different times upon CD40 ligation. NF-kB/
Rel nuclear translocation begins 2 h after stimulation and is sus-
tained for several hours. In contrast, down-regulation of p27
kip-cell
FIGURE 7. Bcl-X expression level is diminished
when PI-3 kinase activity is blocked. A, B cells iso-
lated from wt and c-Rel ko mouse were stimulated
as indicated: 1 h pretreatment with LY294002 and
24 h stimulation with anti-CD40. Immunoblotting
was ﬁrst performed with anti-Bcl-X Ab; next, blot
was stripped and reprobed with anti-Bcl-2 Ab. All
lanes contained equal amounts of protein as deter-
mined by spectrophotometer. B, B cells isolated
from wt and p85a ko mouse were stimulated for
24 h or 48 h with 10 mg/ml anti-CD40 or anti-IgM.
Immunoblotting was performed with anti-Bcl-X Ab.
NS, Nonspeciﬁc band that was used as a loading
control.
FIGURE 6. PI-3K inhibitor effectively blocks AKT
phosphorylation in splenic B cells. B cells isolated
from wt mouse (5 3 10
6/sample) were pretreated for
1 h with 20 mM LY 294002 and further stimulated
with 10 mg/ml anti-CD40 Ab for times indicated.
Western blot was ﬁrst performed with anti-pAKT ac-
cording to manufacturer’s (New England Biolabs) in-
structions. Blot was stripped and reprobed with anti-
AKT Ab.
3865 The Journal of Immunologycycle inhibitor appears only upon 24 h of CD40 stimulation. Fur-
thermore, our study indicates that the down-regulation of p27
kip
isindependent from c-Rel, because in c-Rel ko B cells, p27
kip deg-
radation still occurs normally upon B cell receptor engagement.
4
In contrast to the effects PI-3K exerts on proliferation upon
CD40 stimulation, apoptosis protection seems to proceed normally
even in the absence of the PI-3K activity. Surprisingly, even
though NF-kB/Rel has been implicated in protecting cells from
various apoptotic insults, we found that NF-kB/Rel is not the only
survival pathway mediated by CD40 (Fig. 8). This is concluded
based on our data that establish that CD40-mediated apoptosis pro-
tection is normal in c-Rel ko mouse and in cells treated with the
PI-3K inhibitor. In dissecting the survival pathway, we examined
several known anti-apoptotic molecules. First, AKT kinase, known
to be a direct target of the PI-3K phosphorylation and to prevent
apoptosis, was not activated when PI-3K action has been blocked.
Still, CD40 prevented apoptosis of these cells, suggesting that
CD40-activated cells can remain viable in the absence of AKT.
Remarkably, we demonstrated that Bcl-X expression is regulated
by PI-3K and NF-kB/Rel; and its absence in the c-Rel ko or PI-3K
deﬁcient cells (H.S., T.K., and S.K., unpublished observation) does
not affect the ability of these cells to survive when stimulated via
CD40 receptor. In searching for the remaining CD40-mediated
survival pathways or molecules that confer the protection against
death mediated by PI-3K inhibition, we have indirectly excluded
the c-IAP1 and c-IAP2 members (inhibitor of apoptosis) of
caspase inhibitors (33, 34), as well as transcription factor A-20
(Ref. 11; S. Andjelic, J. Tumang, and H.-Chi Liou, unpublished
data), because these molecules were shown to be dependent on the
NF-kB/Rel activity (3, 35), which is blocked in this case. More-
over, XIAP (X-linked member of the IAP family molecule;
Ref. 36) is also not involved according to several experiments we
performed on XIAP ko mice (kindly provided by Dr. Craig
Thompson, University of Pennsylvania Medical Center; data not
shown), which revealed that the CD40 survival pathway was not
affected by the absence of XIAP (that is NF-kB/Rel-independent).
Thus, the CD40-mediated survival pathways are more complex
than we anticipated, and they are not relying completely on the
induction of known anti-apoptotic molecules, such as Bcl-X, A20,
and IAPs. Previously, we have reported that CD40 stimulation
blocks caspase-3-like activity in normal splenic B lymphocytes
(37). Therefore, it is likely that CD40-induced events block
caspase action through a direct posttranslational modiﬁcation of
certain signaling molecules that are unknown at present, which in
turn inactivate caspases. In addition to searching for these mole-
cules, our future study will be focused on investigating the effect
of CD40 stimulation on preventing the apoptotic events occurring
in mitochondria during the course of programmed cell death (38).
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